Aimee S. Weisner
Aimee S. Weisner's purchase track record
How the stock did after each of Aimee S. Weisner's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/14/2024 | STAA | $67K | +10.2% | -21.2% | +8.6% |
| 8/7/2023 | STAA | $97K | -26.1% | -40.7% | +9.4% |
| 5/17/2023 | LNSR | $131K | +47.3% | -11.0% | +8.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
GKOS Joins Big Stocks Rising on Wednesday; 10‑Year Gains Highlight. GKOS was among the large stocks that gained on Wednesday, adding to its recent upward momentum. A Benzinga piece noted that a $1,000 investment in GKOS 10 years ago would be worth a substantial amount today, underscoring the company's long‑term growth. These stories highlight both the current price action and the company's historical performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.
Transaction History
| LNSR | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 | View on chart |
| GKOS | ▲ Buy | Grant | 1,878 | $0 | 5/28/2026 | View on chart |
| GKOS | ▼ Sell | Gift | 980 | $0 | 2/19/2026 | View on chart |
| GKOS | ▼ Sell | Gift | 980 | $0 | 2/19/2026 | View on chart |
| GKOS | ▲ Buy | Option Exercise | 15,000 | $370K | 2/19/2026 | View on chart |
| GKOS | ▼ Sell | Open Market | 2,153 | $249K | 2/19/2026 | View on chart |
| GKOS | ▼ Sell | Open Market | 5,242 | $611K | 2/19/2026 | View on chart |
| GKOS | ▼ Sell | Open Market | 1,134 | $133K | 2/19/2026 | View on chart |
| GKOS | ▼ Sell | Open Market | 6,471 | $767K | 2/19/2026 | View on chart |
| GKOS | ▲ Buy | Grant | 623 | $0 | 1/2/2026 | View on chart |
| GKOS | ▲ Buy | Grant | 2,108 | $0 | 5/29/2025 | View on chart |
| LNSR | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 | View on chart |
| GKOS | ▲ Buy | Grant | 461 | $0 | 1/2/2025 | View on chart |
| GKOS | ▲ Buy | Option Exercise | 25,000 | $800K | 8/8/2024 | View on chart |
| GKOS | ▼ Sell | Open Market | 25,000 | $3.0M | 8/8/2024 | View on chart |
| STAA | ▲ Buy | Grant | 4,488 | $0 | 6/20/2024 | View on chart |
| GKOS | ▲ Buy | Grant | 1,716 | $0 | 5/30/2024 | View on chart |
| LNSR | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 | View on chart |
| STAA | ▲ Buy | Open Market | 1,750 | $67K | 3/14/2024 | View on chart |
| GKOS | ▲ Buy | Grant | 895 | $0 | 1/2/2024 | View on chart |
| STAA | ▲ Buy | Grant | 3,200 | $100K | 12/29/2023 | View on chart |
| STAA | ▲ Buy | Grant | 497 | $20K | 9/29/2023 | View on chart |
| STAA | ▲ Buy | Open Market | 2,000 | $97K | 8/7/2023 | View on chart |
| STAA | ▲ Buy | Option Exercise | 3,417 | $0 | 6/15/2023 | View on chart |
| GKOS | ▲ Buy | Grant | 3,230 | $0 | 6/1/2023 | View on chart |
| LNSR | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 16,647 | $46K | 5/22/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 22,153 | $57K | 5/19/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 7,700 | $20K | 5/18/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 3,500 | $8K | 5/17/2023 | View on chart |
| GKOS | ▲ Buy | Option Exercise | 10,000 | $73K | 3/8/2023 | View on chart |
| GKOS | ▲ Buy | Grant | 1,572 | $0 | 1/3/2023 | View on chart |
| GKOS | ▲ Buy | Grant | 4,364 | $0 | 6/2/2022 | View on chart |
| LNSR | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 | View on chart |
| GKOS | ▲ Buy | Grant | 1,455 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target
Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.